The next 4 years are going to be exciting and productive for transplant research across a broad range of hematological malignancies. As explained here by David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, the new IMPACT platform will be a series of transplantation trials for patients with leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes and other hematological malignancies. Prof. Marks covers the trials planned for the first and second years of IMPACT, including PRO-DLI (NCT02856464), COSI and ALL-RIC.
IMPACT: expediting transplantation trials
